Get Started

ABBV

AbbVie (ABBV)

AbbVie Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:ABBV

<< Previous 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 Next >>

Date	Time	Source	Headline	Symbol	Company
12/11/2020	4:32PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
12/11/2020	8:24AM	Dow Jones News	AbbVie: CHMP Recommends Approvals of Rinvoq for Psoriatic Arthritis, Ankylosing Spondylitis	NYSE:ABBV	AbbVie Inc
12/11/2020	7:32AM	PR Newswire (US)	CHMP Recommends the Approvals of RINVOQ™ (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ank...	NYSE:ABBV	AbbVie Inc
12/10/2020	8:45AM	PR Newswire (US)	RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in...	NYSE:ABBV	AbbVie Inc
12/09/2020	8:45AM	PR Newswire (US)	Upadacitinib (RINVOQ™) Meets Primary and All Ranked Secondary Endpoints in First Phase 3 Induction Study in Ulcerative Coli...	NYSE:ABBV	AbbVie Inc
12/06/2020	1:00PM	PR Newswire (US)	Combined Data from Multiple Phase 3 Studies of IMBRUVICA® (ibrutinib) Show Efficacy and Safety in High-Risk, Previously Untr...	NYSE:ABBV	AbbVie Inc
12/05/2020	12:45PM	PR Newswire (US)	AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocy...	NYSE:ABBV	AbbVie Inc
12/05/2020	12:30PM	PR Newswire (US)	IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows High Rates of Disease-Free Survival One Y...	NYSE:ABBV	AbbVie Inc
12/02/2020	8:55AM	Dow Jones News	AbbVie Working With Frontier Medicines to Develop Therapeutics	NYSE:ABBV	AbbVie Inc
12/02/2020	8:00AM	PR Newswire (US)	AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against D...	NYSE:ABBV	AbbVie Inc
12/02/2020	8:00AM	PR Newswire (US)	Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against D...	NYSE:ABBV	AbbVie Inc
12/01/2020	8:00AM	PR Newswire (US)	AbbVie to Host Virtual Immunology Strategic Update	NYSE:ABBV	AbbVie Inc
11/24/2020	5:36PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
11/24/2020	8:00AM	PR Newswire (US)	AbbVie to Present at the Evercore ISI Conference and Piper Sandler Healthcare Conference	NYSE:ABBV	AbbVie Inc
11/20/2020	4:06PM	Edgar (US Regulatory)	Securities Registration (section 12(b)) (8-a12b)	NYSE:ABBV	AbbVie Inc
11/19/2020	4:49PM	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NYSE:ABBV	AbbVie Inc
11/18/2020	5:17PM	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:ABBV	AbbVie Inc
11/18/2020	5:05PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
11/18/2020	5:00PM	PR Newswire (US)	AbbVie Announces Expiration and Final Results of Registered Exchange Offers	NYSE:ABBV	AbbVie Inc
11/16/2020	8:05PM	Dow Jones News	Berkshire Hathaway Invests in Drugmakers Seeking Covid-19 Vaccine -- 2nd Update	NYSE:ABBV	AbbVie Inc
11/16/2020	7:37PM	Dow Jones News	Berkshire Hathaway Invests in Drugmakers Seeking Covid-19 Vaccine -- Update	NYSE:ABBV	AbbVie Inc
11/16/2020	7:29PM	Dow Jones News	Berkshire Hathaway Invests in Drugmakers Seeking Covid-19 Vaccine	NYSE:ABBV	AbbVie Inc
11/16/2020	8:00AM	PR Newswire (US)	Allergan Aesthetics Celebrates Second Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day	NYSE:ABBV	AbbVie Inc
11/12/2020	5:57PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
11/12/2020	5:56PM	Edgar (US Regulatory)	Amended Statement of Changes in Beneficial Ownership (4/a)	NYSE:ABBV	AbbVie Inc
11/12/2020	11:10AM	Dow Jones News	AbbVie Vice Chairman, Chief Commercial Officer Carlos Alban to Retire	NYSE:ABBV	AbbVie Inc
11/12/2020	8:00AM	PR Newswire (US)	AbbVie to Present at the Wolfe Research Healthcare Conference	NYSE:ABBV	AbbVie Inc
11/10/2020	8:00AM	PR Newswire (Canada)	Santé Canada approuve le traitement de 8 semaines par MAVIRET® chez les patients infectés par le VHC de génotype 3, attei...	NYSE:ABBV	AbbVie Inc
11/10/2020	8:00AM	PR Newswire (Canada)	Health Canada Approves MAVIRET® 8-Week Treatment Duration for Treatment-Naïve Patients with Genotype 3 Compensated Cirrhosi...	NYSE:ABBV	AbbVie Inc
11/10/2020	7:45AM	InvestorWire	On the Trail of Better Therapeutics for Depression	NYSE:ABBV	AbbVie Inc